Fierce Pharma

NOVEMBER 12, 2024

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it’s laid out th | As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base.

Sales 288

Sales 288

MedCity News

NOVEMBER 12, 2024

Now is the time for health plans to step up and embrace the tools and strategies that will not only meet regulatory demands, but also drive innovation in care delivery. The post Where Medicare Advantage Goes From Here appeared first on MedCity News.

119

119

Fierce Pharma

NOVEMBER 12, 2024

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit,

Sales 284

Sales 284

MedCity News

NOVEMBER 12, 2024

Fort Health’s $5.5 million in funding was led by Twelve Below and Vanterra and included participation from Redesign Health, Blue Venture Fund and True Wealth Ventures. The post Fort Health Secures $5.5M to Expand Access to Integrated Pediatric Mental Health Care appeared first on MedCity News.

114

114

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

NOVEMBER 12, 2024

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval for its liver disease drug Ocaliva has come up short. | Intercept received a complete response letter from the FDA, dashing the company’s hopes of turning Ocaliva’s accelerated green light into a traditional approval for the rare autoimmune disease primary biliary cholangitis.

FDA 288

FDA Pharmaceutical 288

MedCity News

NOVEMBER 12, 2024

Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward. The post Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors appeared first on MedCity News.

Safety 104

Safety Patients Biopharma 104

MedCity News

NOVEMBER 12, 2024

As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies. The post Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale appeared first on MedCity News.

Pharmaceutical 115

Pharmaceutical Biopharma Pharma 115

Fierce Pharma

NOVEMBER 12, 2024

Citing a rosy view of the U.S. | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5 billion. The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way.

Manufacturing 189

Manufacturing 189

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026 as part of a drive to raise its revenues to $80 billion by the end of the decade.The programme – part of the pharma group's Ambition 2030 effort – will include the construction of a new R&D centre at Kendall Square in the heart of the biopharma hub in Cambridge, Massachusetts, and a biologics manufacturing facility in Maryland.

Biopharma 98

Biopharma Sales Manufacturing Pharma 98

Pharmaceutical Technology

NOVEMBER 12, 2024

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.

FDA 104

FDA 104

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

NOVEMBER 12, 2024

Daiichi Sankyo and AstraZeneca give up on their NSCLC application for Dato-DXd, and refile seeking a narrower label

FDA 105

FDA 105

PharmaTimes

NOVEMBER 12, 2024

Insight into double-blind, phase i/ii clinical trial for oesophageal cancer

90

90

pharmaphorum

NOVEMBER 12, 2024

'Game-changer' daily pill to quit smoking returns to NHS after three-year absence after a deal between Teva and NHS England

103

103

PharmaTimes

NOVEMBER 12, 2024

Eco-friendly inhalers aim to reduce environmental impact

85

85

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

NOVEMBER 12, 2024

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.The German group said the CSF-1R inhibitor given as a once-daily, oral dose hit its primary endpoint in the MANEUVER study, achieving an objective response rate (ORR) at week 25 of 54% compared to 3.2% for a matched placebo in patients with TGCT, a rare disease affecting the joints and tendons.

Pharma 103

Pharma Marketing Patients 103

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US. Of this amount, $2 billion will generate over 1,000 new jobs, the company added. AstraZeneca highlighted its US footprint is expanding in multiple areas such as: • a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts • next generation biologics manufacturing facility based in Maryland • cell therapy manufacturing capacity on the W

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

pharmaphorum

NOVEMBER 12, 2024

Neurogene says Rett syndrome gene therapy improves clinical symptoms, but a serious adverse event causes shares to fall

98

98

Pharmaceutical Commerce

NOVEMBER 12, 2024

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

FDA 59

FDA 59

Advertisement

pharmaphorum

NOVEMBER 12, 2024

Virtual wards (also known as hospital at home) allow patients to get the care they need at home safely and conveniently, rather than being in hospital. The NHS is increasingly introducing virtual wards to support people at the place they call home, including care homes. In today’s podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla, about the next generation of digital tools such as wearable medical devices, as well as remote patient monit

Patients 105

Patients Pharma Healthcare Healthcare 105

Pharmaceutical Technology

NOVEMBER 12, 2024

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be overlooked.

Patients 59

Patients 59

Pharmaceutical Commerce

NOVEMBER 12, 2024

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, explains how the use of blockchain technology will become more prominent moving forward.

Pharma 59

Pharma Management 59

pharmaphorum

NOVEMBER 12, 2024

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.The company that made its name by providing saliva-based genetic testing for health and ancestry to millions of people around the world made the decision as part of a major restructuring drive that will see 40% of its workforce lose their jobs.

59

59

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Commerce

NOVEMBER 12, 2024

The latest news for pharma industry insiders.

Pharma 59

Pharma 59

Pharmacy Times

NOVEMBER 12, 2024

Failing is not final, and it does not define what kind of pharmacist or resident a student can be.

58

58

PharmaTech

NOVEMBER 12, 2024

Pharmaceutical Technology® caught up with Brittany Hayes, PhD, Highly Potent & Oncology Platform Director at CordenPharma, after AAPS PharmSci 360 to talk about the challenges and quality requirements involved in the development and manufacture of peptide-based oral dosage forms.

Manufacturing 52

Manufacturing Pharmaceutical 52

Pharmacy Times

NOVEMBER 12, 2024

There were differences in the variables that influenced vaccination decision making for adults aged 18 to 26 years and for parents making the decision to vaccinate their child

55

55

Advertisement

Distribution

PM360

NOVEMBER 12, 2024

The 2025 Healthcare CMO Summit is an exclusive invitation-only event designed to bring together Chief Medical Officers (CMOs) and innovative suppliers and solution providers. Scheduled for February 3-4, 2025 , at The Ritz-Carlton Dallas, Las Colinas , the summit will address key clinical healthcare challenges and relevant market developments. Key Topics The summit will cover a range of critical topics, including: Reviving the Hospital Workforce: Addressing staffing shortages and productivity de

Medical 52

Medical Healthcare Healthcare Safety 52

Pharmacy Times

NOVEMBER 12, 2024

Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.

52

52

PM360

NOVEMBER 12, 2024

The 2025 Healthcare CNO Summit , an exclusive invitation-only event, is scheduled for February 3-4, 2025, at The Ritz-Carlton Dallas, Las Colinas. This premier summit aims to bring together influential Chief Nursing Officers (CNOs) and innovative suppliers to address the evolving challenges in healthcare and foster strategic partnerships. The summit will focus on critical topics essential to the nursing profession, including: CNE Leadership Role: Examining the essential skill set that impacts n

Healthcare 52

Healthcare Healthcare Safety Networking 52

Pharmacy Times

NOVEMBER 12, 2024

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

Patients 52

Patients 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales